Effects of nifedipine on myocardial perfusion and ischemic injury in dogs.

PubWeight™: 1.67‹?› | Rank: Top 3%

🔗 View Article (PMID 679420)

Published in Circ Res on September 01, 1978

Authors

P D Henry, R Shuchleib, L J Borda, R Roberts, J R Williamson, B E Sobel

Articles citing this

Calcium antagonist and the peripheral circulation: differences and similarities between PY 108-068, nicardipine, verapamil and diltiazem. Br J Pharmacol (1983) 1.48

Calcium antagonists: effects on cerebral blood flow and blood-brain barrier permeability in the rat. Br J Pharmacol (1983) 0.92

Calcium antagonists: definition and mode of action. Basic Res Cardiol (1981) 0.90

Coronary collateral reserve during exercise induced ischemia in swine. Basic Res Cardiol (1989) 0.89

Reduction of infarct size in patients with inferior infarction with intravenous glyceryl trinitrate. A randomised study. Br Heart J (1983) 0.85

Effect of nifedipine on enzymatically estimated infarct size in the early phase of acute myocardial infarction. Br Heart J (1988) 0.81

Nifedipine limits infarct size for 24 hours in closed chest coronary embolized dogs. Basic Res Cardiol (1985) 0.81

Importance of myocardial blood flow changes in the protective action of diltiazem in a new model of myocardial ischaemia. Br J Pharmacol (1985) 0.78

The effect of chemical sympathectomy on mitochondrial function in the ischaemic and reperfused myocardium. Br J Pharmacol (1982) 0.78

Nicardipine in models of myocardial infarction. Br J Clin Pharmacol (1985) 0.78

Laboratory and initial clinical studies of nifedipine, a calcium antagonist for improved myocardial preservation. Ann Surg (1981) 0.78

Oxygen at physiological concentrations. A potential, paradoxical mediator of reperfusion injury to mitochondria induced by phosphate. J Clin Invest (1984) 0.78

Protective effects of calcium antagonists against ischaemia and reperfusion damage. Drugs (1991) 0.77

Effect of nifedipine (BAY a 1040) on regional myocardial blood flow in dogs before and during transitory ischemic injury. Basic Res Cardiol (1981) 0.77

Coronary thrombolysis with and without nifedipine in pigs. Basic Res Cardiol (1988) 0.75

Nifedipine effects in severe myocardial ischaemia in the dog due to left anterior descending coronary occlusion with left circumflex coronary artery constriction. Br J Pharmacol (1987) 0.75

Action of amiodarone over the extension and reversibility of experimental myocardial infarction in pigs. Tex Heart Inst J (1984) 0.75

Relations between collateral flow and tissue salvage in the risk area after acute coronary occlusion in dogs: a topographical analysis. Br J Exp Pathol (1986) 0.75

Effects of nifedipine on collateral blood flow at the lateral border of the acutely ischemic myocardium. Basic Res Cardiol (1987) 0.75

Cardioprotection by the calcium antagonist PN 200-110 in the absence and presence of cardiodepression. Br J Pharmacol (1985) 0.75

Alterations in angina threshold with nifedipine during pacing induced angina. Br Heart J (1984) 0.75

Protective effects of pretreatment with intracoronary nifedipine on myocardial ischemia and dysfunction. Cardiovasc Drugs Ther (1990) 0.75

Articles by these authors

A controlled trial of teaching critical appraisal of the clinical literature to medical students. JAMA (1987) 14.20

Factors influencing infarct size following experimental coronary artery occlusions. Circulation (1971) 7.04

Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation (1987) 5.73

Inhibition of telomerase by G-quartet DNA structures. Nature (1991) 5.38

Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med (1985) 5.09

Conformation of the TAR RNA-arginine complex by NMR spectroscopy. Science (1992) 5.08

Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res (1996) 4.75

Identification of a genetic locus for familial atrial fibrillation. N Engl J Med (1997) 4.66

Second dose of measles, mumps, and rubella vaccine: questionnaire survey of health professionals. BMJ (2001) 4.50

Determining optimal therapy--randomized trials in individual patients. N Engl J Med (1986) 4.49

Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med (2001) 4.46

Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med (1998) 4.29

Synthesis of the yeast cell wall and its regulation. Annu Rev Biochem (1982) 4.26

Estimation of infarct size in man and its relation to prognosis. Circulation (1972) 4.19

myo-Inositol 1,4,5-trisphosphate. A second messenger for the hormonal mobilization of intracellular Ca2+ in liver. J Biol Chem (1984) 4.11

Do sick newborn infants benefit from participation in a randomized clinical trial? J Pediatr (1999) 3.98

Comparison of percutaneous and surgical tracheostomies. Chest (1996) 3.56

Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet (1997) 3.40

Alpha helix-RNA major groove recognition in an HIV-1 rev peptide-RRE RNA complex. Science (1996) 3.39

WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol Life Sci (2001) 3.38

A clinician's guide for conducting randomized trials in individual patients. CMAJ (1988) 3.35

Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation (2001) 3.33

Verifying quality and safety in health informatics services. BMJ (2001) 3.31

Preparation of isotopically labeled ribonucleotides for multidimensional NMR spectroscopy of RNA. Nucleic Acids Res (1992) 3.29

Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21

Mutations in the lactose operon caused by bacteriophage Mu. J Mol Biol (1972) 3.17

Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol (1980) 3.14

Quantitative assessment of the extent of myocardial infarction in the conscious dog by means of analysis of serial changes in serum creatine phosphokinase activity. J Clin Invest (1971) 3.11

Hormonal effects on calcium homeostasis in isolated hepatocytes. J Biol Chem (1980) 3.08

Kinetic intermediates in RNA folding. Science (1994) 3.07

Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol (1993) 3.00

The Pumilio protein binds RNA through a conserved domain that defines a new class of RNA-binding proteins. RNA (1997) 2.98

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology (1994) 2.95

Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes (1992) 2.92

Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Investigators of the Ontario Clinical Oncology Group. Int J Radiat Oncol Biol Phys (1994) 2.86

Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol (1982) 2.84

The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol (2001) 2.83

Formation and metabolism of inositol 1,3,4,5-tetrakisphosphate in liver. J Biol Chem (1986) 2.81

A novel loop-loop recognition motif in the yeast ribosomal protein L30 autoregulatory RNA complex. Nat Struct Biol (1999) 2.80

Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver. Proc Natl Acad Sci U S A (1966) 2.76

A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med (1990) 2.73

Kinetic intermediates trapped by native interactions in RNA folding. Science (1998) 2.72

A standard heparin nomogram for the management of heparin therapy. Arch Intern Med (1991) 2.69

It's time for a change to a troponin standard. Circulation (2000) 2.69

The impact of socioeconomic status on health functioning as assessed by the SF-36 questionnaire: the Whitehall II Study. Am J Public Health (1997) 2.65

Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination. Am J Psychiatry (1991) 2.61

Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation (1999) 2.59

Relationship between inositol polyphosphate production and the increase of cytosolic free Ca2+ induced by vasopressin in isolated hepatocytes. J Biol Chem (1984) 2.57

Rubredoxin: a new electron transfer protein from Clostridium pasteurianum. Proc Natl Acad Sci U S A (1965) 2.55

Plasmodium falciparum maturation abolishes physiologic red cell deformability. Science (1984) 2.51

Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5'-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest (1987) 2.48

Inositol trisphosphate and diacylglycerol as intracellular second messengers in liver. Am J Physiol (1985) 2.47

Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature (1990) 2.46

Alpha adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats. J Clin Invest (1980) 2.41

Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. J Am Coll Cardiol (1992) 2.39

Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet (1993) 2.38

Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation (1998) 2.37

Ligand-induced conformational changes observed in single RNA molecules. Proc Natl Acad Sci U S A (1999) 2.35

APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology (2011) 2.35

Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. Circulation (1991) 2.33

Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. J Biol Chem (1993) 2.32

Beyond kinetic traps in RNA folding. Curr Opin Struct Biol (2001) 2.32

Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science (1997) 2.31

Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest (1973) 2.28

Control of citric acid cycle activity in rat heart mitochondria. J Biol Chem (1970) 2.28

The kinetic folding pathway of the Tetrahymena ribozyme reveals possible similarities between RNA and protein folding. Nat Struct Biol (1996) 2.26

Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation (2001) 2.25

Glycolytic control mechanisms. II. Kinetics of intermediate changes during the aerobic-anoxic transition in perfused rat heart. J Biol Chem (1966) 2.24

Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation (2001) 2.23

Novel proteins with binding specificity for DNA CTG repeats and RNA CUG repeats: implications for myotonic dystrophy. Hum Mol Genet (1996) 2.23

Exposing the kinetic traps in RNA folding. Curr Opin Struct Biol (1999) 2.22

A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest (1999) 2.19

Precordial S-T segment elevation mapping: an atraumatic method for assessing alterations in the extent of myocardial ischemic injury. The effects of pharmacologic and hemodynamic interventions. Am J Cardiol (1972) 2.19

Electrocardiographic and clinical criteria for recognition of acute myocardial infarction based on analysis of 3,697 patients. Am J Cardiol (1983) 2.18

Quantitation and early kinetics of inositol lipid changes induced by vasopressin in isolated and cultured hepatocytes. J Biol Chem (1983) 2.18

Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17

Development and implementation of guidelines for family practice: lessons from The Netherlands. J Fam Pract (1995) 2.11

Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation (1972) 2.10

Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation (1999) 2.09

Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation (2000) 2.05

Regulation of free and bound magnesium in rat hepatocytes and isolated mitochondria. J Biol Chem (1986) 2.04

Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. BMJ (1993) 2.03

Depressed myocardial creatine phosphokinase activity following experimental myocardial infarction in rabbit. Circ Res (1970) 2.02

Role of calcium in the hormonal regulation of liver metabolism. Biochim Biophys Acta (1981) 2.01

Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. Circulation (1990) 2.01

Determination of the mitochondrial protonmotive force in isolated hepatocytes. J Biol Chem (1980) 2.00

Glucose and diabetic vascular disease. FASEB J (1992) 2.00

Isolation and sequence analysis of a full-length cDNA for human M creatine kinase. Biochem Biophys Res Commun (1986) 1.96

Role of RNA structure in arginine recognition of TAR RNA. Proc Natl Acad Sci U S A (1993) 1.94

Protection of jeopardized ischemic myocardium by reduction of ventricular afterload. N Engl J Med (1974) 1.92

Medium-chain acyl-CoA dehydrogenase deficiency in children with non-ketotic hypoglycemia and low carnitine levels. Pediatr Res (1983) 1.91

Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci U S A (1989) 1.90

Integrated patient records: another move towards quality for patients? Qual Health Care (1993) 1.88

Does breastfeeding at six months predict cognitive development? Aust N Z J Public Health (1998) 1.87

Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst (1996) 1.86

Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest (1972) 1.86

Control mechanisms of gluconeogenesis and ketogenesis. II. Interactions between fatty acid oxidation and the citric acid cycle in perfused rat liver. J Biol Chem (1969) 1.85

Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med (1982) 1.85

Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med (1999) 1.85